Otilimab
From Wikipedia, the free encyclopedia
Otilimab (development codes MOR103 and GSK3196165) is a fully human antibody which has been developed by the biotechnology company MorphoSys.[1] It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. Otilimab is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.
This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (November 2019) |
Quick Facts Monoclonal antibody, Type ...
Monoclonal antibody | |
---|---|
Type | ? |
Clinical data | |
Other names | GSK3196165; MOR103 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Close